VEGFA and cancer: L+P has especially been used in BRAF wild-type cancers, and a further rationale for the use of this combination is that VEGF-A can induce immunosuppression in the tumor microenvironment by inhibiting dendritic cell maturation and by reducing T-cell infiltration (21).